Connection

SALIM VIRANI to Hyperlipoproteinemia Type II

This is a "connection" page, showing publications SALIM VIRANI has written about Hyperlipoproteinemia Type II.
Connection Strength

2.575
  1. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020 06 18; 22(8):32.
    View in: PubMed
    Score: 0.654
  2. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. Am J Cardiol. 2016 Sep 15; 118(6 Suppl):13A-8A.
    View in: PubMed
    Score: 0.504
  3. Novel therapies for treating familial hypercholesterolemia. Curr Atheroscler Rep. 2014 Jan; 16(1):382.
    View in: PubMed
    Score: 0.418
  4. Prevalence of familial hypercholesterolemia in a country-wide laboratory network in Pakistan: 10-year data from 988, 306 patients. Prog Cardiovasc Dis. 2023 Jul-Aug; 79:19-27.
    View in: PubMed
    Score: 0.203
  5. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.176
  6. Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently? Curr Atheroscler Rep. 2020 07 16; 22(9):44.
    View in: PubMed
    Score: 0.164
  7. Absence of Coronary Artery Calcification in Middle-Aged Familial Hypercholesterolemia Patients Without Atherosclerotic Cardiovascular Disease. JACC Cardiovasc Imaging. 2020 04; 13(4):1090-1092.
    View in: PubMed
    Score: 0.157
  8. Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol. 2015 Sep-Oct; 9(5):676-83.
    View in: PubMed
    Score: 0.116
  9. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Curr Atheroscler Rep. 2015 May; 17(5):508.
    View in: PubMed
    Score: 0.115
  10. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
    View in: PubMed
    Score: 0.035
  11. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.